Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of $72 after the announcement of the proposed acquisition by Novartis (NVS).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA: